Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis.
Delphine BertrandAnke DeprezMichaël DoumenDiederik De CockSofia PazminoAnja MarchalMarc ThelissenJohan JolyElias De MeystBarbara NeerinckxRené WesthovensPatrick VerschuerenPublished in: Musculoskeletal care (2024)
Although some concerns on effectiveness were perceived, both patients and rheumatologists saw potential benefits of dose reduction in terms of safety, societal costs, and application of a personalised approach. As a result, most rheumatologists and patients showed a willingness to consider dose reduction strategies.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- healthcare
- primary care
- systematic review
- mental health
- systemic lupus erythematosus
- diffuse large b cell lymphoma
- patient reported outcomes
- ankylosing spondylitis
- disease activity
- idiopathic pulmonary fibrosis
- patient reported